Atalanta Therapeutics News and Resources

Atalanta Therapeutics has successfully closed a $97 million Series B financing round to support the advancement of its investigational RNA interference (RNAi) therapies for KCNT1-related epilepsy and Huntington’s disease. The financing, co-led by EQT Life Sciences and Sanofi Ventures, brings